Meetings - The ASCO Post

The proportion of early-stage drug trials tackling the most common tumor types has declined sharply since the early 1990s, as less common cancers receive increasing attention in trials, according to n...

solid tumors

immunotherapy

By The ASCO Post Staff / TAT 2019: International Congress on Targeted Anticancer Therapies

TAT 2019: Use of the Lung Immune Prognostic Index in Stratifying Outcomes in Patients Treated With Immune Checkpoint Inhibitors

The Lung Immune Prognostic Index (LIPI) calculated prior to the initiation of treatment may be used to stratify patients with diverse tumor types into groups that significantly associate with outcome ...

issues in oncology

immunotherapy

By The ASCO Post Staff / TAT 2019: International Congress on Targeted Anticancer Therapies

TAT 2019: Barriers to Clinical Trial Access for Adolescents vs Young Adults With Cancer

Compared to young adults, adolescents with the same types of cancer have far less access to immunotherapy and/or targeted therapies, according to findings presented at the TAT 2019–International...

TAT 2019: International Congress on Targeted Anticancer Therapies

TAT 2019: Trends in Distribution of Cancer Type in Phase I Trials

TAT 2019: Use of the Lung Immune Prognostic Index in Stratifying Outcomes in Patients Treated With Immune Checkpoint Inhibitors

TAT 2019: Barriers to Clinical Trial Access for Adolescents vs Young Adults With Cancer

Combination of Two Oral Agents May Improve Progression Free Survival in Patients With Previously Untreated CLL

Primary Analysis of ZUMA-2: Treatment of BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma

Primary Analysis of ZUMA-2 Treatment of BTK Inhibitor-Naive Relapsed Refractory Mantle Cell Lymphoma

FDA Grants Accelerated Approval to Encorafenib Combination for BRAF V600E–Mutant Metastatic Colorectal Cancer

SEQUOIA 5-Year Follow-up Zanubrutinib vs Bendamustine/Rituximab in Treatment-Naive CLL/SLL